<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Dysregulations of osteoblast function induced by gain-of-function genetic mutations in fibroblast growth factor receptors (FGFRs) cause premature fusion of cranial sutures in syndromic <z:hpo ids='HP_0001363'>craniosynostosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The pathogenic signaling mechanisms induced by FGFR genetic mutations in human <z:hpo ids='HP_0001363'>craniosynostosis</z:hpo> remain largely unknown </plain></SENT>
<SENT sid="2" pm="."><plain>In this study, we have used microarray analysis to investigate the signaling pathways that are activated by FGFR2 mutations in <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert</z:e> <z:hpo ids='HP_0001363'>craniosynostosis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Transcriptomic analysis revealed that EGFR and PDGFRalpha expression is abnormally increased in human <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert</z:e> calvaria osteoblasts compared with <z:mp ids='MP_0002169'>wild-type</z:mp> cells </plain></SENT>
<SENT sid="4" pm="."><plain>Quantitative RT-PCR and western blot analyses in <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert</z:e> osteoblasts and immunohistochemical analysis of <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert</z:e> sutures confirmed the increased EGFR and PDGFRalpha expression in vitro and in vivo </plain></SENT>
<SENT sid="5" pm="."><plain>We demonstrate that pharmacological inhibition of EGFR and PDGFR reduces the pathological upregulation of phenotypic osteoblast genes and in vitro matrix mineralization in <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert</z:e> osteoblasts </plain></SENT>
<SENT sid="6" pm="."><plain>Investigation of the underlying molecular mechanisms revealed that activated FGFR2 enhances EGFR and PDGFRalpha <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression via activation of PKCalpha-dependent AP-1 transcriptional activity </plain></SENT>
<SENT sid="7" pm="."><plain>We also show that the increased EGFR protein expression in <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert</z:e> osteoblasts results in part from a post-transcriptional mechanism involving increased Sprouty2-<z:chebi fb="0" ids="28911">Cbl</z:chebi> interaction, leading to <z:chebi fb="0" ids="28911">Cbl</z:chebi> sequestration and reduced EGFR ubiquitination </plain></SENT>
<SENT sid="8" pm="."><plain>These data reveal novel molecular crosstalks between activated FGFR2, EGFR and PDGFRalpha that functionally contribute to the osteoblastic dysfunction in <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert</z:e> <z:hpo ids='HP_0001363'>craniosynostosis</z:hpo>, which may provide a molecular basis for novel therapeutic approaches in this severe <z:e sem="disease" ids="C0263661" disease_type="Disease or Syndrome" abbrv="">skeletal disorder</z:e> </plain></SENT>
</text></document>